Understanding the CEA Marker Test for Cancer
The carcinoembryonic antigen (CEA) test is a blood assay that measures the level of a protein commonly produced by certain types of cancer cells. First identified in the 1960s, CEA has become a routine component of cancer diagnosis and surveillance, especially for gastrointestinal malignancies. While it is not a definitive diagnostic tool on its own, when interpreted alongside imaging, pathology, and clinical findings, CEA provides valuable insight into disease activity.
What Is CEA and Why Is It Measured?
CEA is a glycoprotein normally present in low concentrations in the blood of healthy adults. Elevated levels may arise when cancer cells release excess CEA into the bloodstream. The test is most frequently ordered for:
- Colorectal cancer – the primary indication for CEA monitoring.
- Gastric and esophageal cancers.
- Pancreatic cancer – often used together with CA‑19‑9.
- Breast, lung, and thyroid cancers in selected cases.
- Non‑malignant conditions such as inflammatory bowel disease, pancreatitis, and smoking‑related lung disease.
How the Test Is Performed
A standard venipuncture is all that is required. The blood sample is sent to a clinical laboratory where an immunoassay quantifies CEA concentration, usually reported in nanograms per milliliter (ng/mL). Most laboratories consider a CEA level below 5 ng/mL in non‑smokers and below 10 ng/mL in smokers to be within the normal range.
When Is CEA Testing Recommended?
- Initial staging – After a cancer diagnosis, baseline CEA helps establish a reference point for future comparisons.
- Post‑surgical monitoring – A declining CEA after tumor resection suggests successful removal, while a rise may signal residual disease.
- Adjuvant therapy assessment – During chemotherapy or radiation, periodic CEA checks can indicate treatment response.
- Surveillance for recurrence – Regular testing (often every 3–6 months) enables early detection of recurrence before imaging reveals a lesion.
Interpreting CEA Results
Understanding a CEA value requires context:
- Low or normal levels do not rule out cancer, particularly in early‑stage disease.
- Modestly elevated levels (5–10 ng/mL) may be due to benign conditions or smoking.
- High levels (>10 ng/mL) in a patient with a known malignancy often correlate with
